Form 4: Phathom Pharmaceuticals Director David A. Socks Reports Stock and Option Grants

Director David A. Socks reported the acquisition of stock and option grants in Phathom Pharmaceuticals, according to a Form 4 filing.

Summary

• David A. Socks, a director of Phathom Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 23, 2024, Mr. Socks acquired 10,500 shares of common stock through Restricted Stock Units (RSUs) granted under the Issuer's Non-Employee Director Compensation Program.
• These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the Board.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• Mr. Socks also acquired an option to buy 17,500 shares of common stock at an exercise price of $10.30, also granted under the Non-Employee Director Compensation Program.
• This option vests on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the Board.
• Following these transactions, Mr. Socks directly owns 19,500 shares and indirectly owns 1,211,346 shares through the David A. Socks Family Trust and 409.73 shares through a 401(k).

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard regulatory filing regarding director compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting conditions of the RSUs and stock options.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates compensation practices for non-employee directors at Phathom Pharmaceuticals.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are common practice in the pharmaceutical industry to align director interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Pfizer also utilize similar compensation structures for their board members.
• The vesting schedules tied to continued service are also standard practice to ensure ongoing commitment and expertise on the board.

Stakeholder Impact

• Shareholders may view the director's increased stake in the company positively, as it aligns interests.
• Employees may see this as a standard part of director compensation.

Key Dates